Epi-off corneal collagen cross-linking (CXL) treatment treats progressive keratoconus and ectasia that develops after refractive surgery. The procedure received FDA approval in 2016. Dr. Greenstein and his colleagues conducted a study to determine how well the procedure faired over the years. The study concluded that the treatment appears to remain stable for the majority of patients 10 years postoperatively
You can read more about Dr. Greenstein’s study in the Ophthalmology Times.